{
  "ticker": "VTGN",
  "company_name": "Vistagen Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04754802",
      "title": "PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Social Anxiety Disorder",
      "start_date": "2021-05-24",
      "completion_date": "2022-06-22",
      "enrollment": 0,
      "sponsor": "VistaGen Therapeutics, Inc."
    },
    {
      "nct_id": "NCT05030350",
      "title": "Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)",
      "status": "TERMINATED",
      "phase": "PHASE3",
      "condition": "Social Anxiety Disorder",
      "start_date": "2021-10-01",
      "completion_date": "2022-09-23",
      "enrollment": 0,
      "sponsor": "VistaGen Therapeutics, Inc."
    },
    {
      "nct_id": "NCT03078322",
      "title": "AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Major Depressive Disorder",
      "start_date": "2018-03-05",
      "completion_date": "2019-10-01",
      "enrollment": 0,
      "sponsor": "VistaGen Therapeutics, Inc."
    },
    {
      "nct_id": "NCT06809179",
      "title": "A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Social Anxiety Disorder",
      "start_date": "2025-01-09",
      "completion_date": "2026-12",
      "enrollment": 0,
      "sponsor": "VistaGen Therapeutics, Inc."
    },
    {
      "nct_id": "NCT01483846",
      "title": "Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Neuropathic Pain",
      "start_date": "2011-12",
      "completion_date": "2012-09",
      "enrollment": 0,
      "sponsor": "VistaGen Therapeutics, Inc."
    },
    {
      "nct_id": "NCT03583554",
      "title": "Electrophysiological Biomarkers of AV-101",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Healthy",
      "start_date": "2018-09-01",
      "completion_date": "2019-10-19",
      "enrollment": 0,
      "sponsor": "Marijn Lijffijt, PhD"
    },
    {
      "nct_id": "NCT06358651",
      "title": "Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "Social Anxiety Disorder",
      "start_date": "2024-03-28",
      "completion_date": "2026-10",
      "enrollment": 0,
      "sponsor": "VistaGen Therapeutics, Inc."
    },
    {
      "nct_id": "NCT05011396",
      "title": "PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2",
      "status": "TERMINATED",
      "phase": "PHASE3",
      "condition": "Social Anxiety Disorder",
      "start_date": "2021-08-30",
      "completion_date": "2022-08-16",
      "enrollment": 0,
      "sponsor": "VistaGen Therapeutics, Inc."
    },
    {
      "nct_id": "NCT06615557",
      "title": "Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Social Anxiety Disorder (SAD)",
      "start_date": "2024-09-16",
      "completion_date": "2027-04",
      "enrollment": 0,
      "sponsor": "VistaGen Therapeutics, Inc."
    },
    {
      "nct_id": "NCT04147949",
      "title": "AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia",
      "status": "UNKNOWN",
      "phase": "PHASE2",
      "condition": "Parkinson Disease, Dyskinesia, Medication-Induced, L-Dopa Causing Adverse Effects in Therapeutic Use",
      "start_date": "2022-08",
      "completion_date": "2024-04",
      "enrollment": 0,
      "sponsor": "VistaGen Therapeutics, Inc."
    }
  ],
  "summary": {
    "total_trials": 12,
    "by_phase": {
      "PHASE3": 5,
      "PHASE2": 4,
      "PHASE1": 2,
      "PHASE1, PHASE2": 1
    },
    "by_status": {
      "COMPLETED": 5,
      "TERMINATED": 2,
      "RECRUITING": 2,
      "ACTIVE_NOT_RECRUITING": 1,
      "UNKNOWN": 2
    },
    "active_trials": 3,
    "completed_trials": 5,
    "conditions": [
      "Adjustment Disorder With Anxious Mood",
      "Drug Drug Interaction",
      "Healthy",
      "Major Depressive Disorder",
      "Neuropathic Pain",
      "Parkinson Disease, Dyskinesia, Medication-Induced, L-Dopa Causing Adverse Effects in Therapeutic Use",
      "Social Anxiety Disorder",
      "Social Anxiety Disorder (SAD)"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T13:12:16.779056",
    "search_query": "Vistagen Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Vistagen+Therapeutics,+Inc."
  }
}